Rock Creek Group LP Acquires 2,272 Shares of Pfizer Inc. (NYSE:PFE)

Rock Creek Group LP raised its position in Pfizer Inc. (NYSE:PFE) by 26.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,791 shares of the biopharmaceutical company’s stock after buying an additional 2,272 shares during the quarter. Rock Creek Group LP’s holdings in Pfizer were worth $423,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of PFE. Ameriprise Financial Inc. lifted its stake in Pfizer by 111.3% in the first quarter. Ameriprise Financial Inc. now owns 17,940,336 shares of the biopharmaceutical company’s stock valued at $649,995,000 after buying an additional 9,451,863 shares during the period. BlackRock Inc. grew its position in Pfizer by 2.2% in the 1st quarter. BlackRock Inc. now owns 405,733,970 shares of the biopharmaceutical company’s stock worth $14,699,742,000 after purchasing an additional 8,760,458 shares in the last quarter. Canada Pension Plan Investment Board increased its position in shares of Pfizer by 125.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 13,765,773 shares of the biopharmaceutical company’s stock valued at $498,734,000 after purchasing an additional 7,654,145 shares during the last quarter. Franklin Resources Inc. lifted its stake in Pfizer by 39.6% in the first quarter. Franklin Resources Inc. now owns 26,553,208 shares of the biopharmaceutical company’s stock valued at $962,030,000 after purchasing an additional 7,532,823 shares during the last quarter. Finally, Bank of Nova Scotia raised its position in shares of Pfizer by 113.1% in the first quarter. Bank of Nova Scotia now owns 7,816,581 shares of the biopharmaceutical company’s stock valued at $283,193,000 after purchasing an additional 4,148,877 shares during the period. Institutional investors own 64.93% of the company’s stock.

In other Pfizer news, SVP Jennifer B. Damico sold 2,500 shares of the company’s stock in a transaction on Friday, July 30th. The stock was sold at an average price of $42.86, for a total value of $107,150.00. Following the sale, the senior vice president now owns 11,430 shares of the company’s stock, valued at $489,889.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jennifer B. Damico sold 1,661 shares of the company’s stock in a transaction dated Friday, August 13th. The shares were sold at an average price of $48.30, for a total transaction of $80,226.30. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.

Several brokerages have issued reports on PFE. Morgan Stanley lifted their target price on shares of Pfizer from $42.00 to $45.00 and gave the company an “equal weight” rating in a research report on Thursday, July 29th. Mizuho boosted their target price on Pfizer from $42.00 to $43.00 and gave the company a “neutral” rating in a research note on Friday, July 30th. JPMorgan Chase & Co. raised their price objective on shares of Pfizer from $40.00 to $42.00 and gave the stock a “neutral” rating in a report on Monday. Truist assumed coverage on shares of Pfizer in a report on Tuesday, July 27th. They set a “buy” rating and a $43.00 target price for the company. Finally, SVB Leerink reiterated a “hold” rating and issued a $49.00 price target on shares of Pfizer in a research note on Tuesday. Eleven investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $42.77.

Shares of NYSE PFE opened at $44.71 on Wednesday. The stock has a market capitalization of $250.68 billion, a price-to-earnings ratio of 19.19, a PEG ratio of 1.58 and a beta of 0.74. Pfizer Inc. has a 12 month low of $33.36 and a 12 month high of $51.86. The firm’s 50 day simple moving average is $44.74 and its 200-day simple moving average is $40.35. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.37 and a quick ratio of 1.12.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, July 28th. The biopharmaceutical company reported $1.07 EPS for the quarter, beating analysts’ consensus estimates of $0.97 by $0.10. Pfizer had a return on equity of 26.49% and a net margin of 23.06%. The firm had revenue of $18.98 billion for the quarter, compared to analysts’ expectations of $17.54 billion. During the same period in the prior year, the firm posted $0.78 earnings per share. Analysts anticipate that Pfizer Inc. will post 4.12 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 7th. Stockholders of record on Friday, July 30th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, July 29th. This represents a $1.56 annualized dividend and a dividend yield of 3.49%. Pfizer’s dividend payout ratio is currently 70.27%.

Pfizer Company Profile

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Read More: What are earnings reports?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.